Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2010 Feb 23;33(2):94–98. doi: 10.1002/clc.20705

Peripheral Arterial Tonometry for Risk Stratification in Men With Coronary Artery Disease

Kevin S Heffernan 1,2,✉, Richard H Karas 1,2, Eshan A Patvardhan 1, Haseeb Jafri 1, Jeffrey T Kuvin 1
PMCID: PMC2914463  NIHMSID: NIHMS216075  PMID: 20186990

Abstract

Background

Coronary artery disease (CAD) risk is not fully revealed by traditional risk factors. Identification of a simple, noninvasive tool that allows for detection of high‐risk CAD patients and can be applied in large populations and clinical settings would prove valuable.

Hypothesis

We sought to test the hypothesis that peripheral arterial tonometry (PAT) would be associated with residual risk in men with CAD.

Methods

In this study, finger PAT was used to measure pulse wave amplitude (PWA) during reactive hyperemia (RH) and taken as a measure of microvascular endothelial function in 42 men with stable CAD and well controlled low‐density lipoprotein cholesterol (LDL‐C) levels. Plasma levels of high‐sensitivity C‐reactive protein (hs‐CRP) and lipoprotein‐associated phospholipase A2 (Lp‐PLA2) were measured and used to reclassify men into high‐risk (elevated hs‐CRP and Lp‐PLA2), moderate‐risk (either elevated hs‐CRP or Lp‐PLA2), or low‐risk (low hs‐CRP and Lp‐PLA2) groups.

Results

PWA‐RH was significantly lower in the high‐risk group (1.3 ± 0.04) compared to the moderate‐risk (1.6 ± 0.07, P < 0.05) and low‐risk (2.0 ± 0.1, P < 0.05) groups. According to binary logistic regression, PWA‐RH was a significant predictor of high‐risk status among men with CAD (P < 0.05).

Conclusion

Measurement of peripheral microvascular endothelial function with PAT may be able to distinguish high‐risk men from moderate‐ and low‐risk men with stable CAD and well‐controlled LDL‐C levels and thus aid in residual risk stratification in this at risk cohort. Copyright © 2010 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (161.9 KB).

References

  • 1. Davidson MH, Toth PP. High‐density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol 2007; 100: n32–40. [DOI] [PubMed] [Google Scholar]
  • 2. Bisoendial RJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high‐density lipoprotein in subjects with isolated low high‐density lipoprotein. Circulation 2003; 107: 2944–2948. [DOI] [PubMed] [Google Scholar]
  • 3.Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–3421. [PubMed] [Google Scholar]
  • 4. Suessenbacher A, Frick M, Alber HF, et al. Association of improvement of brachial artery flow‐mediated vasodilation with cardiovascular events. Vasc Med 2006; 11: 239–244. [DOI] [PubMed] [Google Scholar]
  • 5. Kitta Y, Obata JE, Nakamura T, et al. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol 2009; 53: 323–330. [DOI] [PubMed] [Google Scholar]
  • 6. Kuvin JT, Patel AR, Sliney KA, et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J 2003; 146: 168–174. [DOI] [PubMed] [Google Scholar]
  • 7. Kuvin JT, Mammen A, Mooney P, et al. Assessment of peripheral vascular endothelial function in the ambulatory setting. Vasc Med 2007; 12: 13–16. [DOI] [PubMed] [Google Scholar]
  • 8. Dhindsa M, Sommerlad SM, Devan AE, et al. Interrelationships among noninvasive measures of postischemic macro‐ and microvascular reactivity. J Appl Physiol 2008; 105: 427–432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Nohria A, Gerhard‐Herman M, Creager MA, et al. Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. J Appl Physiol 2006; 101: 545–548. [DOI] [PubMed] [Google Scholar]
  • 10. Yeo TW, Lampah DA, Gitawati R, et al. Impaired nitric oxide bioavailability and L‐arginine reversible endothelial dysfunction in adults with falciparum malaria. J Exp Med 2007; 204: 2693–2704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Aversa A, Vitale C, Volterrani M, et al. Chronic administration of sildenafil improves markers of endothelial function in men with type 2 diabetes. Diabet Med 2008; 25: 37–44. [DOI] [PubMed] [Google Scholar]
  • 12. Bonetti PO, Barsness GW, Keelan PC, et al. Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol 2003; 41: 1761–1768. [DOI] [PubMed] [Google Scholar]
  • 13. Hamburg NM, Keyes MJ, Larson MG, et al. Cross‐sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation 2008; 117: 2467–2474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Rubinshtein R, Kuvin JT, Soffler M, et al. Assessment of endothelial function by peripheral arterial tonometry predicts cardiovascular events beyond the Framingham Risk Score. J Am Coll Cardiol 2009; 53: A457. [Google Scholar]
  • 15. Bonetti PO, Pumper GM, Higano ST, et al. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004; 44: 2137–2141. [DOI] [PubMed] [Google Scholar]
  • 16. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000; 139: 272–281. [DOI] [PubMed] [Google Scholar]
  • 17. Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008; 102: 1K–34K. [DOI] [PubMed] [Google Scholar]
  • 18. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C‐reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373: 1175–1182. [DOI] [PubMed] [Google Scholar]
  • 19. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C‐reactive protein. N Engl J Med 2008; 359: 2195–2207. [DOI] [PubMed] [Google Scholar]
  • 20. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein‐associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 2008; 101: 41F–50F. [DOI] [PubMed] [Google Scholar]
  • 21. Lerman A, McConnell JP. Lipoprotein‐associated phospholipase A2: a risk marker or a risk factor? Am J Cardiol 2008; 101: 11F–22F. [DOI] [PubMed] [Google Scholar]
  • 22. Nambi V, Hoogeveen RC, Chambless L, et al. Lipoprotein‐associated phospholipase A2 and high‐sensitivity C‐reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2009; 40: 376–381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein‐associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008; 101: 51F–57F. [DOI] [PubMed] [Google Scholar]
  • 24. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein‐associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006; 26: 1586–1593. [DOI] [PubMed] [Google Scholar]
  • 25. Koenig W, Khuseyinova N, Lowel H, et al. Lipoprotein‐associated phospholipase A2 adds to risk prediction of incident coronary events by C‐reactive protein in apparently healthy middle‐aged men from the general population: results from the 14‐year follow‐up of a large cohort from southern Germany. Circulation 2004; 110: 1903–1908. [DOI] [PubMed] [Google Scholar]
  • 26. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein‐associated phospholipase A2, high‐sensitivity C‐reactive protein, and risk for incident ischemic stroke in middle‐aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005; 165: 2479–2484. [DOI] [PubMed] [Google Scholar]
  • 27. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein‐associated phospholipase A2, high‐sensitivity C‐reactive protein, and risk for incident coronary heart disease in middle‐aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109: 837–842. [DOI] [PubMed] [Google Scholar]
  • 28. Modena MG, Bonetti L, Coppi F, et al. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002; 40: 505–510. [DOI] [PubMed] [Google Scholar]
  • 29. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005; 111: 3481–3488. [DOI] [PubMed] [Google Scholar]
  • 30. Tousoulis D, Charakida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. Postgrad Med J 2008; 84: 368–371. [DOI] [PubMed] [Google Scholar]
  • 31. Clapp BR, Hirschfield GM, Storry C, et al. Inflammation and endothelial function: direct vascular effects of human C‐reactive protein on nitric oxide bioavailability. Circulation 2005; 111: 1530–1536. [DOI] [PubMed] [Google Scholar]
  • 32. Kals J, Kampus P, Kals M, et al. Inflammation and oxidative stress are associated differently with endothelial function and arterial stiffness in healthy subjects and in patients with atherosclerosis. Scand J Clin Lab Invest 2008: 1–8. [DOI] [PubMed] [Google Scholar]
  • 33. Liuba P, Aburawi EH, Pesonen E, et al. Residual adverse changes in arterial endothelial function and LDL oxidation after a mild systemic inflammation induced by influenza vaccination. Ann Med 2007; 39: 392–399. [DOI] [PubMed] [Google Scholar]
  • 34. Tousoulis D, Charakida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. Heart 2006; 92: 441–444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Kharbanda RK, Walton B, Allen M, et al. Prevention of inflammation‐induced endothelial dysfunction: a novel vasculo‐protective action of aspirin. Circulation 2002; 105: 2600–2604. [DOI] [PubMed] [Google Scholar]
  • 36. Vitale C, Cerquetani E, Wajngarten M, et al. In patients with coronary artery disease endothelial function is associated with plasma levels of C‐reactive protein and is improved by optimal medical therapy. Ital Heart J 2003; 4: 627–632. [PubMed] [Google Scholar]
  • 37. Kang SM, Chung N, Kim JY, et al. Relation of vasodilator response of the brachial artery to inflammatory markers in patients with coronary artery disease. Echocardiography 2002; 19: 661–667. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES